Table 2 Relationship between various demographic and clinicopathological characteristics and mutational status (n = 186).
MSS (n = 143), n (%) | MSI (n = 43), n (%) | KRAS wta (n = 121), n (%) | KRAS mutb (n = 65), n (%) | BRAF wt (n = 151), n (%) | BRAF mut (n = 35), n (%) | PIK3CA wt (n = 165), n (%) | PIK3CA mut (n = 21), n (%) | |
|---|---|---|---|---|---|---|---|---|
Gender | ||||||||
Male | 82 (57.3) | 17 (39.5)c | 70 (57.9) | 29 (44.6) | 86 (57.0) | 13 (37.1)c | 93 (56.4) | 6 (28.6)c |
Female | 61 (42.7) | 26 (60.5) | 51 (42.1) | 36 (55.4) | 65 (43.0) | 22 (62.9) | 72 (43.6) | 15 (71.4) |
Age | ||||||||
≤65 | 46 (32.2) | 6 (14.0) | 34 (28.1) | 18 (27.7) | 48 (31.8) | 4 (11.4) | 43 (26.0) | 9 (42.9) |
>66–75 | 46 (32.2) | 16 (37.2) | 42 (34.7) | 20 (30.8) | 48 (31.8) | 14 (40.0) | 59 (35.8) | 3 (14.2) |
≥76 | 51 (35.6) | 21 (48.8) | 45 (37.2) | 27 (41.5) | 55 (36.4) | 17 (48.6) | 63 (38.2) | 9 (42.9) |
Comorbidity | ||||||||
0 | 46 (32.2) | 11 (25.6) | 40 (33.1) | 17 (26.2) | 50 (33.1) | 7 (20.0)c | 49 (29.7) | 8 (38.1) |
1 | 39 (27.3) | 11 (25.6) | 28 (23.1) | 22 (33.8) | 43 (28.5) | 7 (20.0) | 45 (27.3) | 5 (23.8) |
≥2 | 48 (33.5) | 19 (44.2) | 46 (38.0) | 21 (32.3) | 47 (31.1) | 20 (57.1) | 62 (37.6) | 5 (23.8) |
Unknown | 10 (7.0) | 2 (4.6) | 7 (5.8) | 5 (7.7) | 11 (7.3) | 1 (2.9) | 9 (5.4) | 3 (14.3) |
Surgery | ||||||||
Elective | 126 (88.1) | 40 (93.0) | 112 (92.6) | 54 (83.1)* | 134 (88.7) | 32 (91.4) | 149 (90.3) | 17 (81.0) |
Acute | 17 (11.9) | 3 (7.0) | 9 (7.4) | 11 (16.9) | 17 (11.3) | 3 (8.6) | 16 (9.7) | 4 (19.0) |
Subsite | ||||||||
Left-sided colon | 81 (56.6) | 4 (9.3)d | 54 (44.6) | 31 (47.7) | 81 (53.6) | 4 (11.4)d | 77 (46.7) | 8 (38.1) |
Right-sided colon | 62 (43.4) | 39 (90.7) | 67 (55.4) | 34 (52.3) | 70 (46.4) | 31 (88.6) | 88 (53.3) | 13 (61.9) |
Pathological T stage | ||||||||
3 | 142 (99.3) | 43 (100.0) | 120 (99.2) | 65 (100.0) | 151 (100.0) | 34 (97.1) | 164 (99.4) | 21 (100.0) |
4 | 1 (0.7) | 0 (0.0) | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (2.9) | 1 (0.6) | 0 (0.0) |
Differentiation grade | ||||||||
Well/moderate | 98 (68.5) | 16 (37.2)d | 72 (59.5) | 42 (64.6) | 100 (66.2) | 14 (40.0)c | 102 (61.8) | 12 (57.1) |
Poor/undifferentiated | 20 (14.0) | 19 (44.2) | 29 (24.0) | 10 (15.4) | 24 (15.9) | 15 (42.9) | 35 (21.2) | 4 (19.1) |
Unknown | 25 (17.5) | 8 (18.6) | 20 (16.5) | 13 (20.0) | 27 (17.9) | 6 (17.1) | 28 (17.0) | 5 (23.8) |
Lymph nodes evaluated | ||||||||
<10 | 41 (28.7) | 15 (34.9) | 38 (31.4) | 18 (27.7) | 47 (31.1) | 9 (25.7) | 48 (29.1) | 8 (38.1) |
≥10 | 102 (71.3) | 28 (65.1) | 83 (68.6) | 47 (72.3) | 104 (68.9) | 26 (74.3) | 117 (70.9) | 13 (61.9) |
Tumor obstruction | ||||||||
No | 125 (87.4) | 39 (90.7) | 108 (89.3) | 56 (86.2) | 133 (88.1) | 31 (88.6) | 147 (89.1) | 17 (81.0) |
Yes | 18 (12.6) | 4 (9.3) | 13 (10.7) | 9 (13.8) | 18 (11.9) | 4 (11.4) | 18 (10.9) | 4 (19.0) |
Tumor perforation | ||||||||
No | 139 (97.2) | 40 (93.0) | 115 (95.0) | 64 (98.5) | 147 (97.4) | 32 (91.4) | 159 (96.4) | 20 (95.2) |
Yes | 4 (2.8) | 3 (7.0) | 6 (5.0) | 1 (1.5) | 4 (2.6) | 3 (8.6) | 6 (3.6) | 1 (4.8) |
Lymphangioinvasion | ||||||||
No | 138 (96.5) | 42 (97.7) | 118 (97.5) | 62 (95.4) | 147 (97.4) | 33 (94.3) | 159 (96.4) | 21 (100.0) |
Yes | 5 (3.5) | 1 (2.3) | 3 (2.5) | 3 (4.6) | 4 (2.6) | 2 (5.7) | 6 (3.6) | 0 (0.0) |
Microsatellite status | ||||||||
MSS | N/Ae | N/A | 84 (69.4) | 59 (90.8)c | 134 (88.7) | 9 (25.7)d | 129 (78.2) | 14 (66.7) |
MSI | 37 (30.6) | 6 (9.2) | 17 (11.3) | 26 (74.3) | 36 (21.8) | 7 (33.3) | ||
KRAS | ||||||||
Wild type | 84 (58.7) | 37 (86.0)c | N/A | N/A | 86 (57.0) | 35 (100)d | 108 (65.5) | 13 (61.9) |
Mutant | 59 (41.3) | 6 (14.0) | 65 (43.0) | 0 (0) | 57 (34.5) | 8 (38.1) | ||
BRAF | ||||||||
Wild type | 134 (93.7) | 17 (39.5)d | 86 (71.2) | 65 (100)d | N/A | N/A | 133 (80.6) | 18 (85.7) |
Mutant | 9 (6.3) | 26 (60.5) | 35 (28.9) | 0 (0) | 32 (19.4) | 3 (14.3) | ||
PIK3CA | ||||||||
Wild type | 129 (90.2) | 36 (83.7) | 108 (89.3) | 57 (87.7) | 133 (88.1) | 32 (91.4) | N/A | N/A |
Mutant | 14 (9.8) | 7 (16.3) | 13 (10.7) | 8 (12.3) | 18 (11.9) | 3 (8.6) |